Investor Presentation: September 2022

OTCQB:CYTR CORPORATE OVERVIEW September 2022

LadRx Corporation Safe Harbor Statement

THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS "INTENDS," "MAY," "WILL," "PLANS," "EXPECTS," "ANTICIPATES," "PROJECTS," "PREDICTS," ESTIMATES," "AIMS," "BELIEVES," "HOPES," "POTENTIAL"

OR SIMILAR WORDS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF MANAGEMENT AS WELL AS CERTAIN ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAIALABLE TO MANAGEMENT, ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND ARE SUBJECT TO VARIOUS KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES, MANY OF WHICH ARE BEYOND LADRX'S CONTROL, AND CANNOT BE PREDICTED OR QUANTIFIED AND CONSEQUENTLY, RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS AS A RESULT OF VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE RISK FACTORS DISCUSSED IN THE ANNUAL AND QUARTERLY REPORTS THAT LADRX FILES WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THIS PRESENTATION, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF. LADRX RESERVES THE RIGHT TO UPDATE, AMEND OR SUPPLEMENT THE INFORMATION AT ANY TIME IN ITS ABSOLUTE DISCRETION (WITHOUT INCURRING ANY OBLIGATION TO DO SO). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS FREE OF CHARGE ON THE SEC'S WEB SITE AT WWW.SEC.GOV. LADRX ASSUMES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ITS FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

Management and Board

Stephen Snowdy, PhD	Gilad Gordon, MD	John Caloz
CEO	R&D/Regulatory Consultant	CFO
•	Recently joined LadRx	•	Oncology development expert	•	30+ years of CFO
•	PhD Neurobiology University	•	30 years experience		experience in life sciences
	of North Carolina		developing cancer treatments		sector
•	Full-cycle experience: napkin	•	Directly responsible for 50	•	Occulogix, IRIS Int'l,
	drawings to global product		INDs, hundreds of clinical		Synarc, Phoenix Int'l Life
	launch		trials		Sciences

• 20 years of experience in medical executive management
• • Venture capital
  • Medical devices
  • Pharma
  • IPO
  • Public company management

Board of Directors

• Jennifer Simpson, PhD

LadRx Chair of the Board. CEO of Panbela Therapeutics. Former CEO of Delcath, Oncology Lead at Imclone, Product Director Oncology Marketing at Ortho Biotech

• Joel Caldwell

Chair of Audit Committee. 30 years of experience in tax, finance, and auditing.

• Cary J. Claiborne

Chair of the Compensation Committee. CEO of Adial Pharmaceuticals Inc. Former CEO of Prosperity Capital Management, LLC.

Cancer is a massive burden

In 2019, cancer claimed over 10 million lives worldwide1

Leading attributable causes (approx. half of cancers are attributable) are smoking, alcohol use, and high BMI1

Cancer is the second leading cause of death in the US, behind heart disease2

Graphs Adapted from Center for Disease Control, "An Update on Cancer in the United States"

1. "The Global Burden of Cancer…", The Lancet. August 20, 2022. 400:10352. 563-591
2. Center for Disease Control, "An Update on Cancer in the United States"

Investment Highlights

LadRx has developed elegant tumor targeting and
release molecules called LADR that are based on		LadRx is stage-diversified, with LADR-based drugs stretching
small molecular entities (no complex antibodies or		from registrational Phase 2 in pancreatic cancer to late pre-
nanoparticles) allowing for higher dosing and		clinical next-gen drugs
lower off-target tox

• First LADR drug Aldoxorubicin has been licensed to Immunity Bio for $343+ million in milestones and royalties, contingent on regulatory approvals and commercial milestones
• Next-genLADR-based drugs are nearing readiness for IND
• Small and virtual to minimize cash use
• Strong, broad, and global patent portfolio
• Potential short-term upside with licensed product Arimoclomol expected to go to FDA for NDA in 1Q2023 (licensed by KemPharm)